Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H36GeN2 |
Molecular Weight | 341.12 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[Ge]1(CC)CCC2(CCN(CCCN(C)C)C2)CC1
InChI
InChIKey=PWMYMKOUNYTVQN-UHFFFAOYSA-N
InChI=1S/C17H36GeN2/c1-5-18(6-2)11-8-17(9-12-18)10-15-20(16-17)14-7-13-19(3)4/h5-16H2,1-4H3
Molecular Formula | C17H36GeN2 |
Molecular Weight | 341.12 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Spirogermanium [NSC 192965, Spiro-32] is a germanium derivative which was under development by Unimed Pharmaceuticals. Spirogermanium is not a phase or cell cycle specific drug and inhibits DNA, RNA and protein synthesis, the protein synthesis being the most susceptible to this agent. Activity in malignant lymphoma, ovarian cancer, breast cancer, large bowel cancer, and prostatic cancer was reported in the clinical studies. The drug was under clinical investigation against the wide spectrum of solid tumors and malignant lymphomas. Spirogermanium also exhibits antiarthritic and immunoregulatory activities after p.o. administration to rats. Spirogermanium decreased hindleg inflammatory lesions of adjuvant arthritic rats when administered p.o. before or after the development of the arthritic lesions. However, the therapeutic use of spirogermanium has been discontinued because of its high toxicity and the low response rate.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6678870
The dose of 80-120 mg/m2, given by 60' infusion three times a week, was used and tolerated in Phase II clinical studies. The five days continuous infusion schedule has been also under clinical investigation and the doses of 250-300 mg/m2/day were recommended for Phase II studies.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6678870
Spirogermanium has shown cytotoxic activity in vitro against several human tumor cell lines at concentrations (1 ug/ml) that were also found toxic to the cultured rat neurons.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:17 GMT 2023
by
admin
on
Sat Dec 16 15:51:17 GMT 2023
|
Record UNII |
1F01P3Y61E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2139
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C026818
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
C1232
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
41992-23-8
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
DTXSID30194800
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
4683
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
100000083827
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
1F01P3Y61E
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
m10155
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
39075
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY | |||
|
SUB10628MIG
Created by
admin on Sat Dec 16 15:51:17 GMT 2023 , Edited by admin on Sat Dec 16 15:51:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |